KY HB 512
died on adjournmentAN ACT relating to prescription drugs.
Kentucky · 2026 Regular Session · lower
Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.
Quick answers
Did KY HB 512 pass?
No. KY HB 512 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-02-04): to Banking & Insurance (H)
What is KY HB 512 about?
Amend KRS 304.17A-164 to define and redefine terms; establish cost-sharing requirements for prescription drugs; require rebates to be passed through; establish confidentiality requirements for the rebate information; create a new section of KRS 365.880 to 365.900 to provide that the actual amount of rebates received is a trade secret; provide that compliance with prescription drug cost-sharing and rebate requirements shall not be in violation of the Uniform Trade Secrets Act; amend KRS 304.17C-125, 304.38A-115, 18A.225, and 164.2871 to apply the cost-sharing and rebate requirements for prescription drugs to limited health service benefit plans, limited health service organizations, the state employee health plan, and self-insured employer group health plans provided by the governing board of a state postsecondary education institution; apply provisions to health plans issued or renewed on or after January 1, 2027; EFFECTIVE January 1, 2027.
Who sponsors KY HB 512?
M. Proctor, J. Nemes, M. Hart and 8 others are the primary sponsors of KY HB 512.
Description
Amend KRS 304.17A-164 to define and redefine terms; establish cost-sharing requirements for prescription drugs; require rebates to be passed through; establish confidentiality requirements for the rebate information; create a new section of KRS 365.880 to 365.900 to provide that the actual amount of rebates received is a trade secret; provide that compliance with prescription drug cost-sharing and rebate requirements shall not be in violation of the Uniform Trade Secrets Act; amend KRS 304.17C-125, 304.38A-115, 18A.225, and 164.2871 to apply the cost-sharing and rebate requirements for prescription drugs to limited health service benefit plans, limited health service organizations, the state employee health plan, and self-insured employer group health plans provided by the governing board of a state postsecondary education institution; apply provisions to health plans issued or renewed on or after January 1, 2027; EFFECTIVE January 1, 2027.
- Introduced
- 2026-01-28
- Latest action
- 2026-02-04 — to Banking & Insurance (H)
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- M. Proctorprimary
- J. Nemesprimary
- M. Hartprimary
- T. Hamptonprimary
- V. Grosslprimary
- P. Griffeeprimary
- S. Dietzprimary
- J. Callowayprimary
- S. Bratcherprimary
- K. Bantaprimary
- K. Moserprimary
Committees
Not provided by source.
Action timeline
Newest first
2026-02-04
to Banking & Insurance (H)
referral-committee
2026-01-28
to Committee on Committees (H)
referral-committee
2026-01-28
introduced in House
introduction
Versions
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:22:24.357326Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=KY&identifier=HB 512. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.